Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 7,051 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Non Alcoholic Steatohepatitis (NASH)
Interventions: AXA1125, Placebo; Drug
Lead sponsor: Axcella Health, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 57
States / cities: Cullman, Alabama • Tucson, Arizona • Canoga Park, California + 45 more

Conditions: Pulmonary Hypertension
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 18
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more

Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions: Fasinumab, Naproxen, Fasinumab-matching placebo, Naproxen-matching placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 3,307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 58
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 50 more

Conditions: Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Stroke, Hypercholesterolemia
Interventions: lerodalcibep, Placebo; Drug · Other
Lead sponsor: LIB Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Cincinnati, Ohio

Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Placebo, cisplatin/carboplatin, onartuzumab, paclitaxel; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 34
States / cities: Huntsville, Alabama • Scottsdale, Arizona • Bakersfield, California + 28 more

Conditions: Environmental Exposure, PFAS Exposure
Interventions: Streptococcus salivarius 46-SL1, Placebo; Dietary Supplement
Lead sponsor: Cambiotics ApS; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Amyotrophic Lateral Sclerosis
Interventions: MN-166, placebo; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 10
States / cities: Orange, California • Jacksonville, Florida • Augusta, Georgia + 7 more

Conditions: Healthy Volunteers
Interventions: TAK-951 Placebo, TAK-951; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Glendale, California

Conditions: Asthma
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 75
States / cities: Cullman, Alabama • Sheffield, Alabama • Chandler, Arizona + 66 more

Conditions: Postmenopausal Women With Osteoporosis
Interventions: Romosozumab, Alendronate, Placebo to Romosozumab, Placebo to Alendronate; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years to 90 Years · Female only
Enrollment: 4,093 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 32
States / cities: Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 29 more

Conditions: Diabetes Mellitus, Type 2, Obesity
Interventions: Placebo, BI 10773; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 26
States / cities: Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 23 more

Conditions: Healthy Volunteers
Interventions: EI-1071, Placebo; Drug
Lead sponsor: Elixiron Immunotherapeutics Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Small Cell Lung Cancer
Interventions: Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Olaparib 300 mg BID, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Standard Thoracic Radiotherapy, Prophylactic Cranial Irradiation (PCI); Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 35
States / cities: Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more

Conditions: Chronic Kidney Disease
Interventions: Verinurad, Allopurinol, Placebo for Verinurad, Placebo for Allopurinol; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 861 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 54
States / cities: Huntsville, Alabama • Bakersfield, California • Canyon Country, California + 45 more

Conditions: Congestive Heart Failure
Interventions: Nesiritide, Placebo, Saline; Drug
Lead sponsor: Horng Chen; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: JNJ-70033093, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
Interventions: Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo; Drug · Other
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 6 Years to 28 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Pulmonary Arterial Hypertension
Interventions: Empagliflozin 10 MG, Placebo; Drug
Lead sponsor: Gustavo A Heresi, MD, MS; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Baltimore, Maryland • Cleveland, Ohio • Nashville, Tennessee

Conditions: Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
Interventions: Brexpiprazole, OPC-34712, Placebo Oral Tablet; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 37
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Bellflower, California + 25 more

Conditions: Peripheral Arterial Disease
Interventions: Walking assessment, QOL Survey, Ankle pressure at rest and after stress, Muscle Oxygen, Serum MitoQ Level, Needle Biopsy; Diagnostic Test · Other · Procedure
Lead sponsor: University of Nebraska; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Bone Marrow Transplantation
Interventions: Ronacaleret (100mg tablet), Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: ADHD
Interventions: NRCT-101-SR, Placebo; Drug
Lead sponsor: Neurocentria, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Garden Grove, California • Lakeland, Florida • Maitland, Florida + 6 more

Conditions: Carpal Tunnel Surgery, Trigger Finger Disorder, De Quervain Syndrome, Guyon's Canal, Dupuytren Contracture, Morton Neuroma, Tarsal Tunnel Syndrome, Plantar Fasciopathy, Peroneal Nerve Entrapment
Interventions: NAC, NAC 0mg/day (Placebo); Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Obesity
Interventions: NNC0662-0419, Semaglutide, NNC0662-0419 Placebo, Semaglutide placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 24
States / cities: Montgomery, Alabama • Costa Mesa, California • Los Angeles, California + 20 more

Search by objective public record fields.

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)

A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction

A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

Effect of a Dietary Supplement Versus Placebo on Serum PFAS Levels in Male Firefighters

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

A Study of TAK-951 in Healthy Adults

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus

A Study to Evaluate the Safety, Tolerability and Amount of EI-1071 in Blood in Healthy Volunteers

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia

Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction

A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology

An Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses of Ronacaleret in Healthy Human Volunteers

Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)

NAC-REPAIR for Post-surgical Pain

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity